EUCTR2008-006342-25-GB进行中（未招募）不适用
ADMIRE: Does the ADdition of Mitoxantrone Improve REsponse to FCR chemotherapy in patients with CLL: A randomised Phase II Trial of fludarabine, cyclophosphamide and rituximab (FCR) with or without mitoxantrone (M) in previously untreated chronic lymphocytic leukaemia - ADMIRE
eeds Teaching Hospitals NHS Trust0 个研究点开始时间: 2008年11月27日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with the following characteristics are eligible for this study:
- •At least 18 years old.
- •B-CLL with a characteristic immunophenotype.
- •Binet’s Stages B, C or Progressive Stage A
- •Requiring therapy by the IWCLL criteria in that they must have at least one of the following:Evidence of progressive marrow failure as manifested by the development of, or worsening of, anaemia and/or thrombocytopenia.
- •Massive (ie, 6 cm below the left costal margin) or progressive or symptomatic splenomegaly
- •Massive nodes (ie, 10 cm in longest diameter) or progressive or symptomatic lymphadenopathy.
- •Progressive lymphocytosis with an increase of more than 50% over a 2-month period or lymphocyte doubling time (LDT) of less than 6 months as long as the lymphocyte count is over 30x109/L
- •A minimum of any one of the following disease-related symptoms must be present:
- •(a) Unintentional weight loss more than or equal to 10% within the previous 6 months.
- •(b) Significant fatigue (ie, Eastern Cooperative Oncology Group PS 2 or worse; cannot work or unable to perform usual activities)
- •(c) Fevers of greater than 38.0°C for 2 or more weeks without other evidence of infection.
- •(d) Night sweats for more than 1 month without evidence of infection.
- •No prior therapy for CLL.
- •World Health Organisation (WHO) performance status (PS) of 0, 1 or 2
- •Able to provide written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with the following characteristics are ineligible for this study
- •Prior therapy for CLL
- •Active infection.
- •Past history of anaphylaxis following exposure to rat or mouse derived CDR-grafted humanised monoclonal antibodies.
- •Pregnancy, lactation or women of child-bearing potential unwilling to use medically approved contraception whilst receiving treatment.
- •Men whose partners are capable of having children but who are not willing to use appropriate medically approved contraception during the study, unless they are surgically sterile.
- •CNS involvement with CLL.
- •Mantle cell lymphoma.
- •Symptomatic cardiac failure not controlled by therapy or unstable angina not adequately controlled by current therapy (in patients with significant cardiac history the left ventricular function should be assessed and patients with severe impairment should be excluded).
- •Other severe, concurrent diseases or mental disorders.
- •Known HIV positive
- •Patient has active or prior Hepatitis B or C
- •Active secondary malignancy excluding basal cell carcinoma.
- •Persisting severe pancytopenia (neutrophils <0.5 x 109/l or platelets <50 x 109/l) or transfusion dependent anaemia unless due to direct marrow infiltration by CLL
- •active haemolysis (patients with haemolysis controlled with prednisolone at a dose 10mg or less per day can be entered into the trial)
- •Patients with a creatinine clearance of less than 30ml/min (either measured or derived by the Cockcroft formula.
研究者
相似试验
已完成
不适用
Evaluation the effect of adding methylprednisolone to mitoxantrone on progressive multiple sclerosis treatmentMultiple Sclerosis.Demyelinating diseases of the central nervous systemIRCT201107145943N3Yazd University of Medical Sciences70
已完成
2 期
A clinical trial to study the effect of two drugs, granisetron and combination of granisetron-dexamethasone on postoperative nausea and vomiting in children undergoing strabismus surgeyCTRI/2009/091/001000none120
进行中（未招募）
不适用
MITOXANTRONE/GLATIRAMER ACETATE COMBINED TREATMENT IN THE THERAPY OF SECONDARY-PROGRESSIVE MULTIPLE SCLEROSIS - aMICO STUDYsubjects affected by secondary-progressive Multiple SclerosisMedDRA version: 9.1Level: SOCClassification code 10029205EUCTR2009-010661-23-ITAZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA` DEGLI STUDI DI NAPOLI
已完成
不适用
The effect of methylprednisolon plus mitoxantrone in the treatment of progressive multiple sclerosisMultiple sclerosisMultiple sclerosis.IRCT201012245393N1Shahid Sadooghi University of Medical Sciences and Health Services36
招募中
3 期
The efficacy of adding dexamethasone or morphine to 0.25% bupivacaine in ultrasound-guided axillary brachial plexus blockadePatients undergoing surgery of elbow,forearm or hand at Kokha Hospital,Lampang.axillary plexus nerve blockade,ultrasound-guided,bupivacaine,morphine,dexamethasone,postoperative painTCTR20200410002Kokha hospital20